Background: Travel medicine needs are changing. New patterns of travel, including greater travel by individuals from emerging economies with different values in costs, risks and benefits, must be considered. This review aims to (1) highlight selected studies that have been published that address previously identified gaps in knowledge; (2) propose possible ways to consider questions regarding travel medicine practice for travelers from emerging economies, underscoring priorities for research focusing on these important populations; (3) highlight potential deficiencies in relevance of current international guidelines as they pertain to travelers from emerging economies; (4) frame research questions for travelers from emerging economies and (5) consider roles for ISTM in closing the gap. Methods: We reviewed past travel medicine research priorities published in 2010 to identify publications that responded to some research questions posed. We also reviewed CDC and WHO recommendations and assessed their applicability to travelers from emerging economies. Results: Recent publications have responded to some research questions, but gaps remain and new questions have emerged. Re-framing of several key research questions is needed for travelers from emerging economies. Discussion: A new challenge looms for traditional travel medicine fields to identify and attend to knowledge and guideline gaps, particularly to rethink questions regarding travel medicine to make them relevant for travelers from emerging economies. The International Society of Travel Medicine is well positioned to assist emerging economies assess their resources and needs, formulate research priorities and tailor the development of travel medicine into a framework aligned to their requirements.
Introduction
A profound shift is occurring in the global movement of populations with a dramatic increase in travel by residents of low and lower-middle-income countries, especially those from emerging economies 1 , who are traveling to rich countries, to poor countries and in many instances, within country or within continent. As examples, those from large countries like Brazil and China that span many different ecosystems, levels and types of risk, may travel within-country from low risk, highly developed urban areas to a malaria or yellow fever endemic zone. The history of schistosomiasis in Brazil illustrates another scenario, i.e. the southward expansion of disease distribution due to human migration and domestic rural travel. [1] [2] [3] Thus, while within-1 We use the term emerging economies to refer to countries that have low to middle per capita incomes but are advancing rapidly towards the standards of developed countries.
country travel has typically not generated interest in travel medicine consultation or awareness of risk, it should raise alert because levels of disease-specific risks vary by geographic location. The benefit from travel medicine derives from understanding these gradients and types of risks and intervening to protect, prevent, or reduce risks of adverse events. Awareness of or desire for travel medicine consultation depends on availability, culture and economic realities. Preparation for travel depends on knowledge of the traveler's origin, which will define immunological experience from prior exposures and vaccinations, and planned destination(s).
Travel medicine has traditionally focused on preparing the traveler to reduce their individual risk of illness, especially infectious diseases. There should also be focus on preventing the traveler from introducing infections into new areas or bringing pathogens back to a home environment, i.e. vulnerable to introduction or reintroduction of an infection. One key example is malaria, as there are many areas where malaria has been recently eliminated but where competent vectors, suitable climate and living conditions for transmission still exist, posing risks of reintroduction (malaria receptive countries).
The theme of "closing the gap" in travel medicine is one that deserves thoughtful and innovative thinking. Our commentary has the following objectives: (1) highlight selected studies that have been published that address previously identified gaps in knowledge; (2) propose possible ways to consider questions regarding travel medicine practice for travelers from emerging economies, underscoring some priorities for research focusing on these important populations; (3) highlight potential deficiencies in relevance of current international guidelines as they pertain to travelers from emerging economies; (4) frame research questions for travelers from emerging economies and (5) consider roles for ISTM in closing the gap.
Examples of Recent Studies that Address Previously Identified Gaps in Knowledge
In 2010, colleagues from the ISTM Research Committee reviewed questions regarding the practice of travel medicine, identified gaps in knowledge and proposed the research questions that were considered to be of high priority. 4 The authors analysed study designs and described representative samples that had been published relevant to travel medicine, and also highlighted potential research questions and proposed study designs. These priorities were identified with the traveler from developed countries visiting resource-poor areas in mind and were grouped into three sections: pre-travel interventions, safety during travel and post-travel. Since the publication of that review, many studies have been published that respond to some priority research questions and augmented our knowledge, either affirming existing approach in travel medicine or suggesting changes to travel medicine practice. Table 1 displays some research questions selected from the 2010 paper. 4 We list 1-2 questions from each of the three sections and sought recent publications that supplied possible responses. [6] [7] [8] [9] [10] [11] [12] [13] [14] In addition, we incorporate criteria of answerability, research feasibility, deliverability and importance/potential impact into the commentary regarding these studies. 5 , as noted by a 3-point scale based on the number of positive responses to sub-questions described by Wazny et al. 14 Despite these steps forward in the field, some research gaps previously considered to hold priority appear to be less important now, and additional research gaps not identified by Talbot et al. have also emerged. In particular, the increasing volume of travelers from emerging economies and the fledgling field of travel medicine in those regions mean that new research questions have evolved.
Possible Ways to Consider Questions regarding Travel Medicine Practice for Travelers from Emerging Economies

Focus on Destination: Risk Gradient Deviates from Classic Travel Medicine Considerations
Most travel medicine guidelines presume that the traveler will be going from rich and cool to hot and poor country, and from low-to-high risk of infection. The recommendations therefore assume that any preventive interventions will provide benefit for the impending trip plus for subsequent trips that will be undertaken within the period of durability of administered vaccines. For vaccines that provide prolonged or life-long benefit, such as hepatitis A or rabies vaccination, long-term cumulative benefit for all future trips will be achieved. 15 However, for many travelers originating within resource-poor settings, the risk gradient for their trip may be flatter or even inversed (ie moderate-to-moderate risk or high-to-lower risk). This is not because the destination risks are inherently different than for travelers from developed areas (although there is an almost complete lack of data on illness in travelers within or between "higher risk" countries or regions), but rather relates to the fact that their baseline risk of exposure even when at home will be higher. The risk gradient will therefore be highly disease-specific and destination-specific, as is the case for all travelers, but will have the additional complexity of being highly origin-dependent as well. For example, consider the traveler from India who intends to visit Brazil and Peru for a 2-week holiday. While this same destination for a European, American or Australian traveler may well lead to discussions about the need for hepatitis A vaccine, typhoid vaccine, rabies vaccine and travelers' diarrhea management, for the Indian traveler, each of these disease risks might well be lower than if they stayed home. In terms of cumulative risk, the traveler from India may gain most benefit from receiving all these vaccinations (unless they have already been exposed to hepatitis A) despite their reduced incremental travel-related risk, as their cumulative exposure risk to these pathogens likely includes both travel periods and time spent at home. The issues are therefore complex, requiring consideration of a number of aspects:
i. Does the impending travel pose an incremental risk? ii. What is the baseline risk of exposure for this traveler, and should vaccination ideally be considered regardless of the presence of incremental risks from the impending travel? Just as the pre-travel consultation can serve as an opportunity to ensure travelers from developed countries are up-to-date with their routine vaccinations, the pre-travel consultation for those from less developed regions could potentially be viewed as an ideal opportunity to offer vaccinations that are not part of the routine childhood vaccination program (usually because of cost considerations) but from which the individual may glean significant cumulative benefit. The discussion will be complex, especially as behavioural factors may make the trip itself a period of risk, even if disease endemicity is similar at both origin and destination of the traveler, since there are likely differences in activities-such as in where people eatwhen away as compared with when at home. Additionally, the impact of falling ill while traveling may be greater than if someone gets sick at home given potential difficulties in accessing reliable healthcare in an unknown place.
Focus on Home Environment: Influence of Climate, Health Systems and Public Health Infrastructure
The home environment of the traveler from emerging economies should be considered when assessing risk of these travelers. For example, tropical, subtropical and developing areas may be receptive to diseases brought home by returning travelers. Recently, unvaccinated Chinese workers returned from Angola with yellow fever and raised concern for potential spread because of the presence of competent Aedes mosquitoes. [16] [17] [18] Likewise, labour-related travel contributed disproportionately to imported malaria in China, where 70% of >11 000 cases between 2010 and 2014 had exposure in Africa. 19 Importation of
Plasmodium species poses risk to reinfection of local mosquitoes and thus challenges elimination. Repeated dengue virus introductions into China from Southeast Asia during a period of increased regional travel was linked to dengue outbreaks in China in 2013. 20 In the 2016 Zika outbreak in Singapore, foreign workers including many from other Southeast Asian countries were reported to be infected. 21 The climate, presence of vectors, types of housing, sanitation and access to clean water, Routine screening of stool samples for parasitic infection is not indicated for asymptomatic short-term travelers (<3 months), whereas screening for Schistosoma spp. should be offered to travelers with fresh-water contact in endemic regions What is the role of travelers in spread of emerging infections such as chikungunya fever? 14 
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Case series or serosurveys 2 3
Likelihood of answerability, deliverability and importance/potential impact is noted by 3-point scale based on the number of positive responses to the sub-questions (see footnote) 4 .
Scoring guide: 1¼low score, satisfies one sub-question; 2¼intermediate score, satisfies two sub-questions; 3¼highest score, satisfies three sub-questions.
Sub-questions adapted from Wazny et al. healthcare system, surveillance, availability of diagnostics and public health infrastructure of the home countries are especially critical in the impact of the returning traveler.
Another pertinent example is evident in the issue of microbial resistance carriage. [22] [23] [24] There should be worldwide preparedness for receiving returning travelers with resistant organisms, but resource-poor countries with suboptimal medical system and public health infrastructure may not have the capacity to screen, detect and confirm multidrug resistant organisms. Protocols and surveillance systems to prevent secondary spread may also be lacking, leading to significant deleterious effects from imported resistance.
Possible Deficiencies in Relevance of Current International Guidelines as They Pertain to Travelers from Emerging Economies
The likely uptake of travel vaccines and other preventive measures among travelers from resource poor areas may well be lower than for the traditional "western" traveler. This is in part because travel medicine as a field is still in its infancy in many parts of Asia, Africa and Latin America; because availability of vaccines may be lower and costs higher and/or less affordable; and importantly because the perception of risk associated with a trip is likely to be different according to traveler origins. While little research has been done in this area, it may be somewhat akin to the situation of the VFR traveler, where reduced perception of risk results in lower rates of uptake of pre-travel advice and of interventions. For instance, travelers from non-western countries may face higher risks of trauma and tuberculosis (TB) at home; thus recommendations on these topics may hold lower interest. At the same time, immunological experiences of a person from low and lower-middle income countries may make them more or less susceptible to a number of infections they may encounter during travel.
Travelers from resource poor areas may be poorly immunized via vaccines but may have immunity to many infections because of local exposures. There is wide variability in availability, brands and schedules of many of travel vaccines in developing countries, thereby rendering traditional CDC, WHO and other international guidelines of lower or no relevance. Table 2 summarizes recommendations by WHO and CDC and considers their applicability to travelers from emerging economies.
25, 26 For certain sub-groups of travelers, traditional "western" travel medicine guidelines may be even less relevant for those from emerging economies. For example, while the concept of a VFR traveler remains relevant among travelers from developing countries, the standard WHO and CDC definitions may not apply. 25-27 A traveler living in Africa or Asia may undertake a trip for which the main intent is to visit friends and relatives in their country of origin, but may not be traveling from a higher-income country to a country of origin in a low-income area, or from low risk to high risk. Given relatively poor data on many travel-associated risks, especially among travelers from non-western countries, if there is a requirement of a risk gradient in order for the term VFR to be relevant, it would raise many uncertainties. Similarly, the conventional use of the term "business traveler" that applies for Western travelers may not reflect the different types of work-related travel most common among those originating from resource poorer areas. Instead, travel for work may more commonly be as an expatriate or migrant worker. Moreover, the perspective of an "expatriate" among those from non-Western countries may more commonly involve seeing people from elsewhere who have moved to the region (i.e. a "during" travel perspective), as opposed to the Western view of a pre-travel consultation or request for health check following return from an expatriate trip. Again, different data and different guidelines will therefore be needed.
Framing Research Questions for Travelers from Emerging Economies and Role for ISTM
In travel medicine, we should move beyond the idea of international travel from low-to-high risk, instead focusing on a concept of relevant movement, defined by differences in risk (especially modifiable risks) rather than by country borders or absolute distance traveled. Travel medicine also needs to move beyond the concept of exclusive protection of the traveler to also include the protection of both the destination and home populations. Fundamental concepts that have been learned from the western perspective must not be lost if such a transition in the field occurs, but new ideas regarding travel risks need to be added. Additionally, use of now-familiar vocabulary that applies to the "western" traveler should be retained, but additional or alternate descriptors may need to be developed in order to be relevant to the wide range of travel types now occurring.
In consideration of the issues facing travelers from traditional "destination" regions, their different risk gradients, perception of risk, and availability and cost of vaccines and medications, answers to some key topics may aid ISTM as a society to consider research or develop strategies in those regions.
i. Are there national guidelines on travel medicine in emerging economies such as China, India, the Philippines and Ghana? ii. What are the travel patterns from the high-volume countries such as China and India? Consider high-volume origin-destination pairs to identify areas of need for research. iii. Are there guidelines for within country travel (akin to recent advisory that pregnant women avoid travel to Miami due to Zika virus outbreak 28 ), especially for large diverse countries, such as Brazil and China? iv. Are there any developing guidelines to prevent reintroduction of malaria into areas where it has recently been eliminated (malaria-receptive countries or regions)? v. Does travel medicine have an obligation to protect destination and home populations as well as the traveler? How should this be framed? vi. What is the current knowledge base and training needs in emerging economies? Are new systems needed or partnerships and networks with current travel medicine community? vii. What are optimal ways to coordinate and utilize technology to develop travel medicine in emerging economies?
Conclusion
The time to break out of traditional channels of travel medicine thinking has arrived. New patterns of travel, styles and modes Consider for travelers at high risk (e.g. emergency/relief workers).
May be traveling from high risk to low risk destination. Protection may be relevant in home country.
As with all travelers, cholera vaccine is unlikely to be a priority. Travelers' diarrhea discussion, self-Rx
For travelers to high-risk areas, several approaches may be recommended that can reduce, but never completely eliminate, the risk for travelers' diarrhea. These include instruction regarding food and beverage selection, use of agents other than antimicrobial drugs for prophylaxis, and use of prophylactic antibiotics in exceptional situations. Carrying small containers of alcohol-based hand sanitizers (containing 60% alcohol) may make it easier for travelers to clean their hands before eating.
Travelers' diarrhoea most commonly affects individuals traveling from an area of more highly developed standards of hygiene and sanitation to a less developed one. In countries or areas with low standards of hygiene and sanitation and poor infrastructure for controlling the safety of food, drink and drinking-water, risk for travelers' diarrhoea is high. To minimize the risk, travelers should take precautions with all food and drink, even that served in good quality hotels and restaurants. While the risks are greater in poor countries, locations with poor hygiene may be present in any country.
Travelers may be traveling to areas with lower overall risk for travelers' diarrhea, but their individual risk may be related to prior strain-specific exposures. Additionally, there may be differences in behaviours (where and what people eat), and on consequences of infection (may be more difficult to access healthcare while traveling). No data exists on optimal way to advise.
Vector-borne risks Yellow fever (YF) vaccine Governed by International Health Regulations
Governed by International Health Regulations
Issues will be similar for all travelers regardless of place of origin, except for those from South America or endemic areas in Africa (some of whom may receive YF vaccine Comments: risk gradient and travelers from emerging economies as part of their childhood vaccination schedule). These travelers may need vaccination because of where they are coming from rather than where they are going to, and they may need to show proof of vaccination even if they are not going to areas of YF risk. Japanese encephalitis (JE) vaccine
Weigh the overall low risk of travelassociated JE, the high rate of death and disability when JE occurs, the low probability of serious adverse events after immunization, and the cost of the vaccine. Evaluation of a traveler's risk should consider the itinerary, including travel location, duration, activities and seasonality of disease in the areas to be visited. Generally recommended for travelers who plan to spend 1 month in endemic areas during the JE virus transmission season.
The risk for JE is very low for most travelers to Asia, particularly for short-term visitors to urban areas.
For travelers from the Asia-Pacific traveling within-region, the risk may be lower during their trip than when they are at home. Some will have had childhood vaccination and/or boosters, but decisions regarding vaccination will need to consider risks associated both the origin and the destination of the specific traveler.
Malaria chemoprophylaxis
Preventing malaria involves a balance between ensuring that all people at risk for infection use the recommended prevention measures, while preventing rare occurrences of adverse effects of these interventions from unnecessary use. An individual risk assessment should be conducted for every traveler, considering the destination country and the detailed itinerary, including specific cities, types of accommodation, season and style of travel. In addition, conditions such as pregnancy or antimalarial drug resistance at the destination may modify the risk assessment. Depending on the level of risk, it may be appropriate to recommend no specific interventions, mosquito avoidance measures only, or mosquito avoidance measures plus chemoprophylaxis.
Malaria is a common and life-threatening disease in many tropical and subtropicalareas. International travelers to countries or areas at risk of transmission arriving from countries or areas of no risk are at high risk of malaria and its consequences because they lack immunity. Depending on the type of malaria risk in the country or area visited, the recommended prevention method may be mosquito bite prevention only, or mosquito bite prevention in combination with chemoprophylaxis or standby emergency treatment. In light of the spread of counterfeit drugs in some resource-poor settings, travelers may prefer to buy a reliable supply of a reserve antimalarial treatment before departure, so that they can be confident of drug quality should they become ill.
Travelers may have partial immunity if they come from a malaria endemic area, so the balance of risks related to malaria prevention (including chemoprophylaxis) may differ.
Respiratory-borne infections Influenza vaccine Any traveler, including people at high risk for complications of influenza, who did not receive influenza vaccine during the preceding fall or winter and wants to reduce the risk for influenza infection should consider influenza vaccination 2 weeks before departure if they plan to travel to the tropics, with organized tourist groups at any time of year, or to the Travelers with conditions that place them at high risk for complications of influenza should be vaccinated every year. In years when the vaccine strains differ between the northern and southern hemispheres, high-risk individuals traveling from one hemisphere to the other shortly before or during the other hemisphere's influenza season should obtain the vaccination Influenza circulates year-round in tropical areas, so the usual seasonal trends at place of origin may not be relevant for the traveler coming from a non-western setting.
(continued) HBV endemicity may be higher in country of origin than at the destination-although this likely does not obviate the benefits of vaccinating the individual on the basis of their overall cumulative risks (travel plus non-travel periods). Also need to consider when HBV vaccine was introduced into the childhood schedule at the traveler's country of origin to determine whether they are likely to have received HBV vaccination from birth. Behaviours and access to post-exposure care may also be different for travelers.
Human immunodeficiency virus (HIV) risks
Travelers who will be working in a medical setting may have contact with HIV-infected or potentially infected biological materials (and should consider) management of post-exposure prophylaxis in the occupational setting.
In many countries, safe blood and blood products may not be available in all healthcare facilities. No specific advice on which travelers should carry HIV post-exposure prophylaxis.
Depending on country of origin, HIV risks may be higher at the country of origin. However, behaviours and access to post-exposure care may be different in the travelers.
Routine vaccines Measles vaccine
International travelers, including people traveling to industrialized countries, who do not have presumptive evidence of measles immunity and who have no contraindications to a measlescontaining vaccine (i.e. measlesTravelers who are not fully immunized against measles are at risk.
Some Western countries pose a high risk for unvaccinated travelers due to conscientious objectors to measles vaccine. The vaccination rates at both origin and destination need to be carefully considered to determine the incremental risks of (continued)
of transportation, and different values in costs, risks and benefit need to be considered. This provides a fascinating challenge to reframe some of the traditional ways of thinking within the field, and requires bold re-framing of important questions that need to be answered with future research. The International Society of Travel Medicine is well positioned to assist emerging economies to assess their baseline resources and their needs, formulate their research priorities and assist in the development of their nascent practice of Travel Medicine. Similar issues regardless of country of origin, except for those coming from a country (e.g. Pakistan) with circulating wild polio infection, who may need "exit" vaccination.
